Frequently Asked Questions
The market is segmented based on , By Birth Defects (Cataracts, Cleft Lip or Palate, Congenital Heart Disease, Contractures, Diaphragmatic Hernia, Genital Malformations, Glaucoma, Misshapen Skull, Missing Fingers or Toes, Missing or Incomplete Arms or Legs, Spina Bifida), Chronic Disease (Bleeding Disorders, Childhood Cancers, Kidney or Urinary Tract Disease, Slow Growth or Short Stature, Cystic Fibrosis, Sickle Cell Disease, Thalassemia), Application (Inherited Disorder Testing, Pharmacogenetics Testing (Pgx), Human Leukocyte Antigen (Hla) Testing, Oncology Testing, Others) – Industry Trends and Forecast to 2030.
.
The Global Pediatric Genetic Disease Treatment Market size was valued at USD 10.86 USD Billion in 2022.
The Global Pediatric Genetic Disease Treatment Market is projected to grow at a CAGR of 9.1% during the forecast period of 2023 to 2023.
The major players operating in the market include Abbott, Pfizer , ELITechGroup, PerkinElmer , Quest Diagnostics, AutoGenomics, F. Hoffmann-La Roche Ltd, Bio,Rad Laboratories, Precipio, Biosystems S.A., Sarepta Therapeutics, BioMarin, GW Pharmaceuticals plc, Vertex Pharmaceuticals orporated, Shire, Amgen , Illumina, Invitae Corporation, Progenity, Aetna , GeneDx.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
